Drug profile · INN
dichlorphenamide
ORMALVI
dichlorphenamide (ORMALVI) is a carbonic anhydrase xii inhibitor. Associated with Xeris Biopharma Holdings. Route of administration: oral. Current US regulatory status: approved.
Drug details — dichlorphenamide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 1
- Data quality
- 0.89
Quick answer
dichlorphenamide (ORMALVI) is a carbonic anhydrase xii inhibitor. Associated with Xeris Biopharma Holdings. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Carbonic anhydrase XII inhibitor
Primary target: Carbonic anhydrase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is dichlorphenamide?
dichlorphenamide (ORMALVI) is a carbonic anhydrase xii inhibitor. Associated with Xeris Biopharma Holdings. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dichlorphenamide?
ORMALVI is a marketed brand name for dichlorphenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dichlorphenamide?
dichlorphenamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.